|
0 Comments
This report was originally published at South Carolina Policy Council. South Carolina enters Fiscal Year 2027 with strong economic momentum but growing fiscal risk. Payroll employment expanded by 3.1 percent year over year, while the unemployment rate edged up to 4.3 percent in August 2025, according to the U.S. Bureau of Labor Statistics. The labor market remains among the most dynamic in the Southeast, supported by migration inflows and diversified job growth in professional services, health care, and hospitality, as detailed in the Richmond Fed’s South Carolina Economic Snapshot. Behind this strength, however, the state budget tells a different story. Over the past decade, recurring spending has outpaced population growth plus inflation. The Americans for Tax Reform’s Sustainable Budget Project estimates that in 2024, South Carolina’s state-fund expenditures exceeded population growth plus inflation by $6.8 billion and all-fund spending by $9.9 billion—nearly $36 billion in cumulative overspending since 2015. This report outlines the FY 2027 South Carolina Responsible Budget (SCRB): a framework combining a Responsible Spending Limit (RSL) tied to less than population growth plus inflation and a surplus-trigger buydown that automatically channels certified surpluses into lowering personal income taxes. Drawing from SCPC’s Path to Prosperity roadmap, ATR’s Sustainable Budget Project, and Club for Growth Foundation’s analysis in the Sustainable Budgeting Blueprint, the SCRB presents a credible path to eliminating South Carolina’s income tax. Polling by the South Carolina Policy Council shows that 74 percent of voters support income-tax elimination and 68 percent favor a spending cap based on population growth plus inflation. Both of these policy positions have majority support among Republicans, Democrats , and Independents. The economic conditions, public mandate, and policy tools now align. The South Carolina Responsible Budget provides the blueprint to translate this moment into lasting prosperity. Read the full report below. Your browser does not support viewing this document. Click here to download the document.
Originally published on Substack. Yesterday I had the honor of presenting at the U.S. Capitol alongside Grover Norquist with Tax Reform for the release of my new paper, “Will Washington Hand the Future of Biotech to Beijing?” I’m grateful for the opportunity to share this research with Members of Congress, staff, and leaders who care about the future of American innovation. The issue at stake couldn’t be more serious. Biotechnology is not just another industry. It’s about whether the next generation of cures for cancer, Alzheimer’s, or rare diseases are discovered here—or in Beijing or likely not at all. It’s about whether American patients get access to those treatments first—or whether they’re forced to wait behind lines set by governments. America Leads When Government Steps Back
America didn’t become the global biotech leader through central planning. We got here because government—imperfectly, and only occasionally—pulled back to let markets breathe (though not enough).
These were not examples of government fixing markets. They were examples of government loosening its grip just enough for markets to work. And even then, Washington never really let go. The state is still deeply embedded in biotech—funding, regulating, approving, and increasingly, dictating prices. Washington’s Wrong Turn Instead of stepping back further, Washington is going the other direction. Biden’s Inflation Reduction Act gave bureaucrats sweeping power to dictate drug prices. And this May, President Trump signed a Most Favored Nation executive order tying U.S. prescription drug prices to foreign government caps. The problem of foreign freeloading is real. Countries like Canada and Germany deliberately underpay by imposing price controls, knowing U.S. patients will shoulder the cost. The Council of Economic Advisers estimates Americans fund nearly 70% of global patented drug profits despite being only one-third of global GDP. But importing their broken systems here won’t solve it. Research published at National Bureau of Economic Research found that slashing U.S. drug prices by 40–50% would cut early-stage R&D by 30–60%. That doesn’t make medicines cheaper. It makes them disappear. The MFN order may not cause cuts that steep, but it sends a signal to investors: Washington is willing to cap returns. That chills investment—and cures vanish. Meanwhile, Washington already directs about 60% of all U.S. healthcare spending. That isn’t a free market. It’s government control. And when government dominates, price signals vanish, competition collapses, and costs rise. That’s not a failure of markets. That’s a failure of government. Meanwhile, China Surges Ahead While we smother our innovators, China is racing forward with its Made in China 2025 strategy.
China doesn’t need to out-innovate us. It just needs to let Washington keep kneecapping our own innovators. Incentives Drive Innovation Drug development costs more than $2 billion per therapy and takes a decade or more. Most attempts fail. The only reason investors take that risk is the possibility of earning a return and reinvesting in the next breakthrough. Take away that incentive, and the pipeline dries up. Europe proves the point. Patients there wait years longer for new therapies, and many drugs never arrive at all. That’s the cost of government-imposed price controls. The lesson is clear: government intervention suffocates incentives. Freedom unleashes them. A Better Path Forward Here’s how Congress can protect America’s biotech leadership:
Closing Thoughts This debate isn’t about whether markets work—they do. It’s about whether government will keep distorting them. The Constitution itself recognized the power of protecting inventors’ rights. America’s prosperity didn’t come from government programs. It came from the freedom to innovate, compete, and serve people. The more Washington steps back, the more patients win. If Washington doubles down on control, China will gladly take our place. But if we trust freedom, America will remain the global leader in cures and innovation. I’m grateful to Grover Norquist and Americans for Tax Reform for hosting this event at the Capitol, and to everyone committed to restoring freedom in healthcare. The path forward is clear: end government failures, protect property rights, empower patients, and let people prosper. Read Report: https://atr.org/race-for-innovation/ Eliminating Property Taxes in Texas: Real Options for True Homeownership and Economic Prosperity9/3/2025
Originally published at Texans for Fiscal Responsibility. Updated in September 2025 with the latest property tax data. Property taxes are a financial burden that Texans can no longer afford to endure. Over the past 27 years, Figure 1 illustrates how property taxes have increased by an unsustainable 364%, far outpacing population and inflation growth of 149%. For Texans, this is not just an economic issue—it’s a question of fairness and freedom. Property taxes make homeowners perpetual renters, burden renters, and businesses, and restrict economic opportunity. Despite six legislative attempts since 1997, Table 1 shows that the latest structural problems driving property tax growth remain unaddressed and unresolved. Texans need bold, permanent solutions. Two pathways to finally eliminate property taxes include:
The Problem: Why Property Taxes Must Go Property taxes are burdensome in both design and execution. Figures 2 and 3 highlight how property taxes have increased more than fourfold since 1998. This unchecked growth has created severe economic distortions and eroded true homeownership. Property taxes affect all families who are homeowners, renters, and business owners, as noted in the Texas Comptroller’s 2023 report. Figure 4 from the Texas Comptroller’s Office shows that estimated school property taxes’ final incidence (i.e., burden) hits families across Texas. Source: Texas Comptroller’s Tax Exemptions and Tax Incidence Report
Homestead Exemptions: A Misguided Solution While well-intentioned, homestead exemptions, which exempt an amount from the appraised value for property taxes, are not the answer:
A Lack of Accountability Most local governments, except special purpose districts and some other small tax jurisdictions with a maximum of 8%, can raise property taxes by 3.5% on existing property (with no limitation on new property) without direct voter approval. With these loopholes in current law, county and city taxes increased by over 10% last year. This lack of oversight enables runaway spending and taxes. To address this, all property tax increases above 0% must require voter approval, with a 0% growth rate unless explicitly approved by the public. This means that as the County appraisal office does appraisals, the property tax rate determined by the local governing body must go down, so that the tax revenue (levy) collected doesn’t change from the prior period. This levy cap system makes appraisal caps or tax rate caps unnecessary, and the no-new-revenue rate is what the levy cap should be. The limitation must be on the levy collected from all property taxes, which a strong spending limit that covers spending from all revenue, including property taxes, sales taxes, and other revenues, should ultimately do. This would make it less relevant where the tax revenue comes from as the spending and, therefore, taxes are held in check and hopefully reduced. Pathway 1: Surplus-Driven Buydowns The surplus-driven buydown approach systematically reduces property taxes over time by dedicating state budget surpluses to lowering tax rates until they are zero. This gradual method ensures that essential services remain funded during the transition. How It Works
Scenarios of Surplus Buydowns to Eliminate Property Taxes
Pros of Surplus Buydown Method
A redesigned tax system in Texas would swap sales taxes for property taxes, preferably with a strong spending state and local spending limit and surplus buydown to reduce sales and other taxes. This approach depends on:
2. Adjust State and Local Sales Tax Base and Rates:
3. Ensure Spending Restraint, Transparency, and Accountability:
Pros of Tax System Redesign
Some suggest implementing a Value-Added Tax (VAT) instead of a broader sales tax to fund the property tax swap. This would be a mistake:
Texas must avoid adopting European-style tax systems that stifle economic freedom and growth. Recommendations for Legislators To ensure success, any plan to eliminate property taxes must include the following:
Texas must move beyond temporary fixes and fundamentally transform the state-local tax system. Whether through surplus-driven buydowns or a redesigned sales tax, the result will be a freer, fairer, and more prosperous state. Texans deserve true property ownership, economic opportunity, and a government that operates within its means.
Let’s end property taxes and empower Texans to prosper. The time to act is now. Originally posted at Americans for Tax Reform. Today, Americans for Tax Reform released the Empower Patients Initiative, co-authored by Vance Ginn, Ph.D., staff economist at ATR, president of Ginn Economic Consulting, and former Chief Economist at the White House Office of Management and Budget under President Trump, and Deane Waldman, M.D., M.B.A., a nationally recognized pediatric cardiologist, former Director of the Center for Healthcare Policy at the Texas Public Policy Foundation, and Emeritus Professor at the University of New Mexico. With the One Big Beautiful Bill (OBBB) laying the groundwork for expanding Health Savings Accounts (HSAs), there’s momentum to give Americans more control over their health care. The Empower Patients Initiative builds on that foundation—offering a workable, fiscally sustainable plan to restore free-market exchanges between patients and doctors, without third parties making the decisions while taking trillions of dollars away from care. America’s healthcare crisis isn’t about a lack of money—it’s about a lack of agency. We spend over $4.8 trillion a year, yet patients face longer wait times, higher prices, and fewer choices. Government rules and third-party payers have hijacked decision-making, leaving people with “coverage” but no real choice and no timely access to care. The Empower Patients Initiative charts a better path—one that empowers people, not bureaucracies. Key reforms include: • Putting the $23,968 that employers now give to insurance companies directly into workers’ hands • Creating No-limit HSAs—a single, tax-free account with no caps, no expiration, and no federal controls • Deregulating providers and insurers to allow real competition and innovation • Replacing Medicaid’s broken funding formula with federal block grants to states, giving them the flexibility to design safety nets that serve the truly vulnerable—not bureaucrats in Washington • Eliminating BURRDEN (Bureaucracy, Unnecessary Rules and Regulations, Directives, Enforcement, and Noncompliance) that wastes up to $2.4 trillion annually This approach gets Washington out of the way and puts patients back at the center—restoring choice, driving down costs, providing care when needed, and improving outcomes. We urge legislators, congressional staff, grassroots leaders, and the public to read the full initiative on the ATR website—and the companion book, Empower Patients: Two Doctors’ Cure for Healthcare, to learn how we can finally fix American healthcare. Your browser does not support viewing this document. Click here to download the document.
|
Vance Ginn, Ph.D.
|
||||||||||||||
RSS Feed